India, Feb. 18 -- The share of this company, which focuses on generic and speciality pharmaceuticals, including antibiotics, cardiovascular (CVS), central nervous system (CNS), antiretrovirals, anti-allergics, and gastroenterology products are in focus after the USFDA flags concerns on its manufacturing facility

With a market capitalization of Rs 67,271 crore, Aurobindo Pharma Ltd's shares on Wednesday made a day low of Rs 1,130 per share, down by 4.7 percent from the previous day's close price of Rs 1,184.65 per share. The share of the company trades at a way undervalued P/E of 19x compared to the industry P/E of 27.9x.

What happened Unit VII Inspection: The US FDA carried out an inspection of Aurobindo Pharma's Unit-VII oral solid dos...